A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
- Conditions
- Active Noninfectious Uveitis Affecting the Posterior Segment
- Interventions
- Drug: REGN7041
- Registration Number
- NCT07218770
- Lead Sponsor
- Regeneron Pharmaceuticals
- Brief Summary
This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection.
The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood and the fluid in the eye at different times
* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 72
- Diagnosis of non-infectious anterior, intermediate, posterior or panuveitis (For anterior uveitis, there must be evidence of inflammation affecting the posterior segment), as defined in the protocol
- Active disease at baseline, as defined in the protocol
- Part A only: Best Corrected Visual Acuity (BCVA) of ≤65 and >10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of worse than or equal to 20/50 and better than 20/630) at the screening visit and on day 1
- Part B only: BCVA of <75 and >10 ETDRS letters (Snellen equivalent of worse than 20/32 and better than 20/630) at the screening visit and on day 1
Key
- BCVA of ≤30 ETDRS letters (Snellen equivalent of 20/250 or worse) at the screening visit and/or on day 1
- Intraocular Pressure (IOP) <5 mm Hg at the screening visit and/or on day 1
- IOP >25 mm Hg on day 1. Participants are permitted to take IOP-lowering eye drops
- Confirmed or suspected infectious uveitis, as defined in the protocol
NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Sequential Single Ascending Dose Cohorts REGN7041 - Sequential Multiple Ascending Dose Cohorts REGN7041 -
- Primary Outcome Measures
Name Time Method Occurrence of Treatment-Emergent Adverse Events (TEAEs) Through Week 24
- Secondary Outcome Measures
Name Time Method Concentrations of REGN7041 in serum Through Week 24 Incidence of Anti-Drug Antibodies (ADAs) to REGN7041 in serum Through Week 24 Magnitude of ADAs to REGN7041 in serum Through Week 24